Business Description | Loan Book / AUM | |
---|---|---|
![]() |
Retail LendingMulti-product retail lending platform, ‘digital-at-the-core’ DHFL acquisition significantly increased the size and scale of the retail lending business |
` 21,552 Crores1 |
![]() |
Wholesale LendingLoans to residential & commercial real estate developers, as well as, corporates in select sectors |
` 43,633 Crores |
![]() |
Alternative AUMFund management business; partnerships with marquee investors such as CDPQ and Bain Capital Credit |
~$ 1 Bn(Funds committed) |
![]() |
Life InsuranceJV with Prudential International Insurance Holdings; industry leader in the Defense segment |
` 1,099 Crores(FY 2022 Gross written premium) |
![]() |
Investments in Shriram20% stake in SCL2 |
` 5,095 Crores3 |
Notes:
(1) In addition, acquired ` 18,747 Crores of fee-earning, securitised assets (off-balance sheet) with DHFL, now managed by PEL
(2) SCL: Shriram Capital Limited and SCUF: Shriram City Union Finance
(3) Investments in SCUF based on market value; SCL based on book value, including accumulated profits
Business Description | FY 2022 Revenue | |
---|---|---|
![]() |
Contract Development and Manufacturing Organisation (CDMO)API and formulation manufacturing with a presence across the drug lifecycle, including research, development, clinical, and commercial manufacture. |
` 3,960 Crores |
![]() |
Complex Hospital GenericsPortfolio of inhalation anaesthesia, injectable anaesthesia and pain management, injectable intrathecal treatment, and other injectables products sold across the globe. |
` 2,002 Crores |
![]() |
India Consumer HealthcareIndia Consumer healthcare business in India with a portfolio of multiple brands in attractive segments and a nationwide sales & marketing infrastructure |
` 741 Crores |
![]() |
JV with Allergan (49% stake)A market leader in the fastgrowing ophthalmology category in India, offering medications for diseases like glaucoma, dry eye, infections, and inflammations. |
` 414 Crores |